Abbvie Inc (ABBV) concluded trading on Wednesday at a closing price of $187.34, with 4.38 million shares of worth about $820.43 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 2.41% during that period and on June 04, 2025 the price saw a gain of about 0.05%. Currently the company’s common shares owned by public are about 1.77B shares, out of which, 1.76B shares are available for trading.
Stock saw a price change of 2.32% in past 5 days and over the past one month there was a price change of -4.45%. Year-to-date (YTD), ABBV shares are showing a performance of 5.42% which increased to 16.19% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $159.77 but also hit the highest price of $218.66 during that period. The average intraday trading volume for Abbvie Inc shares is 7.92 million. The stock is currently trading 1.27% above its 20-day simple moving average (SMA20), while that difference is up 0.13% for SMA50 and it goes to -0.92% lower than SMA200.
Abbvie Inc (NYSE: ABBV) currently have 1.77B outstanding shares and institutions hold larger chunk of about 74.13% of that.
The stock has a current market capitalization of $330.92B and its 3Y-monthly beta is at 0.49. PE ratio of stock for trailing 12 months is 79.88, while it has posted earnings per share of $2.35 in the same period. Its PEG reads 5.25 and has Quick Ratio of 0.64 while making debt-to-equity ratio of 49.22. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ABBV, volatility over the week remained 0.18% while standing at 1.82% over the month.
Stock’s fiscal year EPS is expected to rise by 20.82% while it is estimated to increase by 14.45% in next year. EPS is likely to grow at an annualized rate of 15.22% for next 5-years, compared to annual growth of -14.67% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Citigroup on May 14, 2025 offering a Neutral rating for the stock and assigned a target price of $205 to it. Coverage by Cantor Fitzgerald stated Abbvie Inc (ABBV) stock as an Overweight in their note to investors on April 22, 2025, suggesting a price target of $210 for the stock. On December 10, 2024, BofA Securities Resumed their recommendations, while on December 05, 2024, Daiwa Securities Downgrade their ratings for the stock with a price target of $180. Stock get an Outperform rating from Leerink Partners on November 22, 2024.
